COU-AA-302
IA3 data. Note: All secondary end points remain significant after adjusting for multiplicity testing.
Abiraterone
Prednisone
Median
(months)
Median
(months)
HR (95% CI)
p Value
Secondary end points
Time to opiate use (cancer-
related pain)
NR
23.7
0.71 (0.59-0.85)
0.0002
Time to chemotherapy
initiation
26.5
16.8
0.61 (0.51-0.72)
< 0.0001
Time to ECOG PS
deterioration
12.3
10.9
0.83 (0.72-0.94)
0.0052
Time to PSA progression
11.1
5.6
0.50 (0.43-0.58)
< 0.0001
Exploratory end points
Time to BPI-SF pain
interference progression
10.3
7.4
0.80 (0.68-0.93)
0.0049
Time to degradation in
FACT-P (total score)
12.7
8.3
0.79 (0.67-0.93)
0.0046
Rathkopf et al. Eur Urol 2014; [epub]
COU-AA-302: Objetivos secundarios/análisis final
